Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Zydus Lifesciences Ltd (ZYDUSLIFE) is currently trading at 903.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Zydus Lifesciences Limited is an innovation-driven, vertically integrated pharmaceutical group operating across generics, branded formulations, biosimilars, vaccines, APIs, consumer wellness and MedTech, with ~41 manufacturing sites, eight R&D centres, and global revenues around $2.75 billion, positioning the company as a major Indian pharma exporter and a top generics player in the US. Q3 FY26 financials show robust execution: consolidated revenues of Rs. 68,645 mn (▲30% YoY), EBITDA of Rs. 18,164 mn (26.5% margin), R&D spend at 8.8% of revenues, and adjusted net profit of Rs. 11,109 mn; organic capex remains high at Rs. 4,637 mn for the quarter, while net debt widened to Rs. 28,728 mn at quarter end. The product and innovation pipeline is advancing materially: Zydus plans to file an NDA for Saroglitazar Magnesium in the US imminently, has achieved several biosimilar and specialty milestones including a first‑in‑class Menkes disease approval (Zycubo), and holds licensing deals for large‑molecule biosimilars and a CE mark for its Andy robotic surgical system. Strategic M&A and partnerships are reshaping growth engines: full consolidation of Comfort Click doubled down Consumer Wellness scale (Q3 consumer revenue ▲113% YoY), acquisition of US biologics facilities from Agenus enables a Bio CDMO roadmap, and management retained a Rs. 5,000 crore QIP approval as an optional funding lever for future acquisitions. Geographic and portfolio diversification is visible: Pharma remains ~81% of sales with North America contributing 41% of revenues, India branded formulations outperformed the market with 14% growth, International Markets accelerated (▲38% YoY), and consumer wellness and MedTech are emerging, higher‑growth adjacencies supporting margin and top‑line resilience.
Over the past 52 weeks, Zydus Lifesciences Ltd has traded between a low of ₹797.05 and a high of ₹1,059.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Zydus Lifesciences Ltd has a market capitalization of approximately 91,572.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Zydus Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.91 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 91,572.32 Cr, Zydus Lifesciences Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Zydus Lifesciences Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Zydus Lifesciences Ltd is 17.91. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Zydus Lifesciences reported a 30.3% year-on-year revenue growth to ₹6,864.5 crore and a 9% increase in adjusted net profit to ₹1,110 crore, driven by strong performance in its North America and India businesses.
Zydus Lifesciences reported a 30.3% year-on-year increase in revenue to Rs 6,864.5 crore and a 30.9% rise in EBITDA to Rs 1,816.4 crore. Net profit grew by nearly 2% to Rs 1,042 crore.
The 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay, is the most significant announcement. It directly supports Zydus's strategic focus on developing and manufacturing biologics and biosimilars, aiming to make India a global hub.
Zydus Lifesciences is in talks to acquire US biopharma firm Ardelyx, potentially by purchasing a controlling stake or its key molecules. Ardelyx is valued at approximately $1.6 billion.
Bearish
1
Neutral
7
Bullish
6
Bearish
23
Neutral
7
Bullish
16
Bearish
22
Neutral
0
Bullish
10
Product Launch & Partnership
Zydus Lifesciences launched ANYRA™, India’s first indigenously developed Aflibercept 2 mg biosimilar for retinal diseases (AMD, DME, RVO, DR, mCNV) and signed agreements with Regeneron and Bayer to expand access.
Regulatory Approval
Zydus Lifesciences received USFDA final approval for Bosentan 32 mg tablets for oral suspension to treat pediatric pulmonary arterial hypertension; to be manufactured in Ahmedabad; U.S. sales ~$9.3M (IQVIA Dec‑2025).
Press Release
Zydus Lifesciences received USFDA final approval for Bosentan 32 mg tablets for oral suspension for pediatric pulmonary arterial hypertension; product to be made at Ahmedabad SEZ, US sales ~USD 9.3M (IQVIA Dec 2025).
Product Launch
Zydus Lifesciences launched PEPAIR, India’s first affordable Oscillating Positive Expiratory Pressure (OPEP) drug‑free handheld device priced at Rs.990 with a 3‑resistance system to aid mucous clearance for COPD, asthma and bronchiectasis in partnership with AeroDel.
Product Launch
Zydus Lifesciences launched PEPAIR™, India’s first affordable Oscillating Positive Expiratory Pressure (OPEP) handheld device (Rs.990/unit) with a 3‑resistance system, in partnership with AeroDel, for COPD, asthma and bronchiectasis airway clearance.
Earnings Call Transcript
Q3 FY26 transcript: consolidated revenue ₹68.6bn (+30% YoY), EBITDA ₹18.2bn (+31%) and adjusted PAT ₹11.1bn (+9%); US approvals/launches, Comfort Click & Amplitude consolidated, biosimilar licenses and upcoming Saroglitazar NDA.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1348.00 | 1,08,978 Cr | 22.90 | 3.31 | 1.19 | 16.53 | 21.05 | 11.32 | |
1283.00 | 1,06,904 Cr | 19.23 | 2.97 | 0.62 | 16.03 | 18.66 | 10.16 | |
2223.80 | 1,01,749 Cr | 20.43 | 5.18 | 0.54 | 22.03 | 21.92 | 13.94 | |
910.05 | 91,572 Cr | 17.91 | 3.62 | 1.21 | 19.44 | 19.08 | 10.52 | |
2072.00 | 85,665 Cr | 46.03 | 5.60 | 0.00 | 11.45 | 12.34 | 6.26 | |
1171.20 | 67,358 Cr | 19.26 | 1.92 | 0.00 | 9.77 | 12.69 | 6.63 | |
5463.60 | 65,331 Cr | 27.20 | 4.90 | 0.82 | 17.69 | 18.13 | 11.95 |
Zydus Lifesciences Limited is an innovation-driven, vertically integrated pharmaceutical group operating across generics, branded formulations, biosimilars, vaccines, APIs, consumer wellness and MedTech, with ~41 manufacturing sites, eight R&D centres, and global revenues around $2.75 billion, positioning the company as a major Indian pharma exporter and a top generics player in the US.
Q3 FY26 financials show robust execution: consolidated revenues of Rs. 68,645 mn (▲30% YoY), EBITDA of Rs. 18,164 mn (26.5% margin), R&D spend at 8.8% of revenues, and adjusted net profit of Rs. 11,109 mn; organic capex remains high at Rs. 4,637 mn for the quarter, while net debt widened to Rs. 28,728 mn at quarter end.
The product and innovation pipeline is advancing materially: Zydus plans to file an NDA for Saroglitazar Magnesium in the US imminently, has achieved several biosimilar and specialty milestones including a first‑in‑class Menkes disease approval (Zycubo), and holds licensing deals for large‑molecule biosimilars and a CE mark for its Andy robotic surgical system.
Strategic M&A and partnerships are reshaping growth engines: full consolidation of Comfort Click doubled down Consumer Wellness scale (Q3 consumer revenue ▲113% YoY), acquisition of US biologics facilities from Agenus enables a Bio CDMO roadmap, and management retained a Rs. 5,000 crore QIP approval as an optional funding lever for future acquisitions.
Geographic and portfolio diversification is visible: Pharma remains ~81% of sales with North America contributing 41% of revenues, India branded formulations outperformed the market with 14% growth, International Markets accelerated (▲38% YoY), and consumer wellness and MedTech are emerging, higher‑growth adjacencies supporting margin and top‑line resilience.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
91,572 Cr
Low Risk
17.9
26.5
—
3.6
1,059.00
797.05
Sales CAGR
Profit CAGR
ROE
ROCE
